Company intelligence / Profile preview
Bionic Sight
New York, New York, United Statesbionicsightllc.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BS01 gene therapy received RMAT designation from FDA in February 2025 for treatment of retinitis pigmentosa patients with advanced stage vision loss. The company reported "potentially game changing results" in its Phase 1/2 trial and is now preparing for Phase 3 trials.
- Therapeutic areas
- Ophthalmology
- Modalities
- Gene therapyOptogenetics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Applied Genetic Technologies Corporation (AGTC)
Beyond the preview
Go deeper on Bionic Sight.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bionic Sight.